Cancer Monoclonal Antibodies Global Market Opportunities And Strategies To 2030: COVID 19 Growth And Change

Cancer Monoclonal Antibodies Market 2022 – By Monoclonal Antibody Therapies (Avastin, Herceptin, Keytruda, Opdivo, Darzalex, Perjeta), By Application (Breast Cancer, Blood Cancer, Lung Cancer, Brain Tumor, Colorectal Cancer, Cervical Cancer, Gastric Cancer), By End-User (Hospitals, Research Laboratories), And By Region, Opportunities And Strategies – Global Forecast To 2030

Name: Cancer Monoclonal Antibodies Global Market Opportunities And Strategies To 2030: COVID 19 Growth And Change
Creator: The Business Research Company
License: https://www.thebusinessresearchcompany.com/privacy-policy

Cancer Monoclonal Antibodies Global Market Opportunities And Strategies To 2030: COVID 19 Growth And Change

Starting Price : $5000.00 $3500.00 | Pages : 219 | Published : June 2022 | | Format : pdf

Purchase Options

Request a Sample

Request For Discount

Customise Your Report

Item added to cart!

Request For Proposal

Request For Regional Data

Need assistance or more information before the purchase?

Enquire Before Buying

Proud Members Of

Cancer Monoclonal Antibodies Market Definition

The cancer monoclonal antibodies market consists of sales of cancer monoclonal antibodies and related services by entities (organizations, sole traders and partnerships) that produce cancer monoclonal antibodies that prevent or inhibit the proliferation, maturation or survival of cancer cells. Cancer monoclonal antibodies recognize and bind to proteins in a highly selective manner. By binding specifically to proteins expressed by cancer cells they can selectively target these transformed cells and destroy them by activating the immune response or delivering cytotoxins.

Book your 30 minutes free consultation with our research experts

Cancer Monoclonal Antibodies Market Size

The global cancer monoclonal antibodies market reached a value of nearly $53,785.1 million in 2020, having increased at a compound annual growth rate (CAGR) of 20.47% since 2015. The global cancer monoclonal antibodies market size is expected to grow from $53,785.1 million in 2020 to $86,056.7 million in 2025 at a rate of 9.9%. The global cancer monoclonal antibodies market size is then expected to grow at a CAGR of 7.3% from 2025 and reach $122,283.7 million in 2030.

Growth in the historic period resulted from emerging markets growth, increase in R&D expenditure, increased geriatric population, and increased preference for biological treatments. Factors that hindered the growth of the cancer monoclonal antibodies market during the historic period include low healthcare access, failures of cancer monoclonal antibodies in clinical trials, usage of surrogate endpoints in clinical trials, and pricing pressures from regulators.

Going forward, increasing prevalence of cancer, expanding global access, and rise in healthcare expenditure will drive the growth. Factors that could hinder the growth of the cancer monoclonal antibodies market in the future include high cost in development of monoclonal antibodies, and stringent regulatory guidelines.

Cancer Monoclonal Antibodies Market Drivers

The key drivers of the cancer monoclonal antibodies market include:

Increasing Prevalence Of Cancer

The rising prevalence of cancer cases across the globe is likely to contribute to the growth of the cancer monoclonal antibody market during the forecast period. According to the Union for International Cancer Control (UICC)’s GLOBOCAN 2020: New Global Cancer Data published in December 2020, the global cancer burden has risen to 19.3 million cases and 10 million cancer deaths in 2020. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. Furthermore, according to the International Agency for Research on Cancer (IARC), globally 1 in 5 people develop cancer during their lifetime, and 1 in 8 men and 1 in 11 women die from the disease. As suggested by the new estimates, more than 50 million people are living within five years of a past cancer diagnosis. Socio-economic risk factors and the elderly population are a major cause for increasing cancer cases, thereby driving the growth of the cancer monoclonal antibodies market.

Cancer Monoclonal Antibodies Market Restraints

The key restraints on the cancer monoclonal antibodies market include:

High Cost In Development Of Monoclonal Antibodies

The high costs involved in the development of monoclonal antibodies with advanced techniques act as a major restrain for the market due to the complex production process, expensive biological and chemical materials, and clinical trials, as well as required safety, efficacy, and quality tests. Advanced equipment is required for the large-scale production of monoclonal antibodies that encompass multiple disulfide bonds and post-translational modifications, and this equipment is expensive. Clinical efficacy is usually achieved by injecting large amounts of monoclonal antibodies into the system, which means that large quantities are required to be produced for each treatment, thus increasing the cost. Thus, the high development costs in using these advanced techniques will restrain market growth.

Cancer Monoclonal Antibodies Market Trends

Major trends influencing the cancer monoclonal antibodies market include:

Humanized Cancer Monoclonal Antibodies

Humanized antibodies are the antibodies derived from non-human species whose proteins have been modified to enhance their resemblance to natural human antibodies. The humanized antibodies can be generated through recombinant DNA methods using an appropriate vector and expression in mammalian cells. The humanized antibody has advantages such as reduced immunogenicity, and increased serum half-life of the mAb in humans. The first fully human therapeutic antibody, adalimumab (Humira), an anti-tumor necrosis factor a (TNFa) human antibody was approved in 2002 by the US FDA for rheumatoid arthritis. As of December 2019, 30 fully human monoclonal antibodies and 1 fully human bispecific antibody (Lumoxiti®) have been approved for clinical use.

Technological Advancements in Gene Sequencing and Target Gene Selection

Technological advancements such as gene sequencing and target gene selection are used by pharmaceutical companies in the cancer monoclonal antibodies market. The increase in adoption of genome wide analysis, global tumour expression profiling and artificial intelligence is promoting opportunities for improved target selection and personalized medicine. Various powerful techniques such as hybridoma technology, phage display, and B-cell amplification with the help of PCR have been developed for the construction of numerous types of antibodies and antibody fragments with widespread structural modifications. Scientists developed various hybridoma technologies, which involve the fusion of antibody-producing cells—clones of a unique antibody-producing parent cell—with immortalized myeloma tumor cells. Combinations of tumor-targeted mAbs with ICB (Immune checkpoint blockade) have demonstrated that there are several encouraging avenues for maximizing the clinical benefit of mAb therapy. These technologies have led to the development of highly-effective monoclonal antibodies, which are gaining widespread preference among healthcare professionals.

Opportunities And Recommendations In The Cancer Monoclonal Antibodies Market

Opportunities –The top opportunities in the cancer monoclonal antibodies market segmented by monoclonal antibody therapies will arise in the others segment, which will gain $15,622.0 million of global annual sales by 2025. The top opportunities in segment by application will arise in the other segment, which will gain $12,137 million of global annual sales by 2025. The top opportunities in segment by end user will arise in the hospitals segment, which will gain $6,302.6 million of global annual sales by 2025. The cancer monoclonal antibodies market size will gain the most in the USA at $16,361.4 million.

Recommendations –To take advantage of these opportunities, The Business Research Company recommends the cancer monoclonal antibodies companies to focus on humanized cancer monoclonal antibodies, invest in artificial intelligence, focus on technological advancements in gene sequencing and target gene selection, invest In R&D, focus on investment in targeted and combination therapy, expand in developed markets, focus on product innovation through strategic collaborations, set up authorized distributors and sales representatives, expand in emerging markets, provide competitively priced offerings, focus on securing long-term supply contracts with healthcare institutions, offer value-based pricing, increase visibility through SEO campaigns, participate in trade shows and events, leverage social media to maximize reach, focus on increasing awareness, partnerships with end-users, targeting hospitals and pharmacies to spread awareness.

Cancer Monoclonal Antibodies Market Segmentation

The cancer monoclonal antibodies market is segmented by monoclonal antibody therapies, by application and by end user.
By Monoclonal Antibody Therapies -
The cancer monoclonal antibodies market is segmented by monoclonal antibody therapies into:

a) Avastin
b) Herceptin
c) Keytruda
d) Opdivo
e) Darzalex
f) Perjeta
g) Others

The others market was the largest segment of the cancer monoclonal antibodies market segmented by monoclonal antibody therapies, accounting for 30.4% of the total in 2020. Going forward, the darzalex market is expected to be the fastest growing segment in the cancer monoclonal antibodies market segmented by monoclonal antibody therapies, at a CAGR of 17.8% during 2020-2025.
By Application -
The cancer monoclonal antibodies market is segmented by application into:

a) Breast Cancer
b) Blood Cancer
c) Lung Cancer
d) Brain Tumor
e) Colorectal Cancer
f) Cervical Cancer
g) Gastric Cancer
h) Others

The others was the largest segment of the cancer monoclonal antibodies market segmented by application, accounting for 28.7% of the total in 2020. Going forward, the others segment is expected to be the fastest growing segment in the cancer monoclonal antibodies market segmented by application, at a CAGR of 12.3% during 2020-2025.
By End-User -
The cancer monoclonal antibodies market is segmented by end-user into:

a) Hospitals & Clinics b) Research Laboratories c) Others

The hospitals was the largest segment of the cancer monoclonal antibodies market segmented by end user, accounting for 72.5% of the total in 2020. Going forward, the others segment is expected to be the fastest growing segment in the cancer monoclonal antibodies market segmented by end user, at a CAGR of 10.1% during 2020-2025.
By Geography- The cancer monoclonal antibodies market is segmented by geography into

o Asia Pacific
- • China
- • India
- • Japan
- • Australia
- • Indonesia
- • South Korea

• USA

• Brazil

• UK
• Germany
• France

• Russia

North America was the largest region in the cancer monoclonal antibodies market, accounting for 47.9% of the total in 2020. It was followed by Asia Pacific, and Western Europe. Going forward, the fastest-growing regions in the cancer monoclonal antibodies market will be South America, and Africa where growth will be at CAGRs of 14.0% and 12.8% respectively. These will be followed by Middle East, and North America, where the markets are expected to grow at CAGRs of 12.1% and 10.7% respectively.

Cancer Monoclonal Antibodies Market Competitive Landscape

Major Competitors are:

• F. Hoffmann-La Roche Ltd

• Merck & Co., Inc

• Bristol Myers Squibb Company

• Johnson & Johnson

• Amgen Inc

Other Competitors Include:

AstraZeneca plc

Eli Lilly and Company

Pfizer Inc

Regeneron Pharmaceuticals Inc

Sanofi S.A

Innovent Biologics

Sino biological

Shanghai Junshi Biosciences

Shanghai Henlius Biotech

Intas bio

Zydus Cadila

Ranbaxy

Takeda pharmaceuticals

AbbVie Inc

Biogen Idec

Bayer AG

Novartis AG

BiosanaPharma

WuXi

GlaxoSmithKline

Teva UK Limited

Abbott Laboratories

Fujifilm

Procos SpA

BSP Pharmaceuticals

Genmab

Insysbio

Rani Therapeutics

Emisphere Technologies, Inc

Enteris BioPharma

Allena Pharmaceuticals

Apotex

Gilead Sciences

Eurofarma

Teuto Brasileiro

BioMarin Pharmaceutical

BIONOVIS BRASIL

Ecopharm

Hypermarcas

Ache

Libbs Farmaceutica

Julphar

Spimaco Addwaeih

Hikma Pharmaceuticals

Tabuk

Novo Nordisk

BBI Solutions

APC Pharma

EPICIO

Medical Union Pharmaceuticals

South Egypt Drug Industries Co. Pharmaceutical

Vacsera Pharma

Aspen Pharmacare

Amoun Pharmaceuticals Co Ltd

54gene

Baxter International

Altis Biologics

Cipla

Medpro South Africa

Genzyme

1. Cancer Monoclonal Antibodies Market Executive Summary

2. Table of Contents

3. List of Figures

4. List of Tables

5. Report Structure

6. Introduction

6.1. Segmentation By Geography

6.2. Segmentation By Monoclonal Antibody Therapies

6.3. Segmentation By Application

6.4. Segmentation By End User

7. Cancer Monoclonal Antibodies Market Characteristics

7.1. Market Definition

7.2. Market Segmentation By Monoclonal Antibody Therapies

7.2.1. Avastin

7.2.2. Herceptin

7.2.3. Keytruda

7.2.4. Opdivo

7.2.5. Darzalex

7.2.6. Perjeta

7.2.7. Others

7.3. Market Segmentation By Application

7.3.1. Breast Cancer

7.3.2. Blood Cancer

7.3.3. Lung Cancer

7.3.4. Brain Tumor

7.3.5. Colorectal Cancer

7.3.6. Brain Tumor

7.3.7. Cervical cancer

7.3.8. Gastric cancer

7.3.9. Others

7.4. Market Segmentation By End User

7.4.1. Hospitals

7.4.2. Research Laboratories

7.4.3. Others

8. Cancer Monoclonal Antibodies Market Trends And Strategies

8.1. Product Innovation Through Strategic Collaborations

8.2. Humanized Cancer Monoclonal Antibodies

8.3. Investment in Artificial Intelligence

8.4. Technological Advancements in Gene Sequencing and Target Gene Selection

8.5. R&D Investments

8.6. Investment in Targeted and Combination Therapy

9. Impact Of COVID-19 On The Cancer Monoclonal Antibodies Market

9.1. Introduction

9.2. Supply Chain Issues

9.3. Clinical Trial Delays

9.4. Impact On Major Players

9.5. Future Outlook

10. Global Cancer Monoclonal Antibodies Market Size And Growth

10.1. Market Size

10.2. Historic Market Growth, 2015 – 2020, Value ($ Million)

10.2.1. Drivers Of The Market 2015 – 2020

10.2.2. Restraints of The Market 2015 – 2020

10.3. Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

10.3.1. Drivers Of The Market 2020 – 2025

10.3.2. Restraints On The Market 2020 – 2025

11. Global Cancer Monoclonal Antibodies Market Segmentation

11.1. Global Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

11.2. Global Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

11.3. Global Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

12. Cancer Monoclonal Antibodies Market, Regional And Country Analysis

12.1. Global Cancer Monoclonal Antibodies Market, By Region, Historic and Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

12.2. Global Cancer Monoclonal Antibodies Market, By Country, Historic and Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

13. Asia-Pacific Cancer Monoclonal Antibodies Market

13.1. Asia-Pacific Cancer Monoclonal Antibodies Market Overview

13.1.1. Region Information

13.1.2. Market Information

13.1.3. Background Information

13.1.4. Government Initiatives

13.1.5. Regulatory Bodies

13.1.6. Regulations

13.1.7. Major Associations

13.1.8. Taxes Levied

13.1.9. Corporate Tax Structure

13.1.10. Investments

13.1.11. Major Companies

13.2. Asia-Pacific Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

13.3. Asia-Pacific Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

13.4. Asia-Pacific Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

13.5. Asia-Pacific Cancer Monoclonal Antibodies Market: Country Analysis

13.6. China Cancer Monoclonal Antibodies Market

13.7. China Cancer Monoclonal Antibodies Market Overview

13.7.1. Region Information

13.7.2. Market Information

13.7.3. Background Information

13.7.4. Government Initiatives

13.7.5. Regulatory Bodies

13.7.6. Regulations

13.7.7. Major Associations

13.7.8. Taxes Levied

13.7.9. Corporate Tax Structure

13.7.10. Investments

13.7.11. Major Companies

13.8. China Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

13.9. China Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

13.10. China Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

13.11. India Cancer Monoclonal Antibodies Market

13.12. India Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

13.13. India Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

13.14. India Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

13.15. Japan Cancer Monoclonal Antibodies Market

13.16. Japan Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

13.17. Japan Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

13.18. Japan Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

13.19. Australia Cancer Monoclonal Antibodies Market

13.20. Australia Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

13.21. Australia Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

13.22. Australia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

13.23. Indonesia Cancer Monoclonal Antibodies Market

13.24. Indonesia Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

13.25. Indonesia Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

13.26. Indonesia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

13.27. South Korea Cancer Monoclonal Antibodies Market

13.28. South Korea Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

13.29. South Korea Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

13.30. South Korea Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

14. Western Europe Cancer Monoclonal Antibodies Market

14.1. Western Europe Cancer Monoclonal Antibodies Market Overview

14.1.1. Region Information

14.1.2. Market Information

14.1.3. Background Information

14.1.4. Government Initiatives

14.1.5. Regulations

14.1.6. Regulatory Bodies

14.1.7. Major Associations

14.1.8. Taxes Levied

14.1.9. Corporate Tax Structure

14.1.10. Investments

14.1.11. Major Companies

14.2. Western Europe Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

14.3. Western Europe Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

14.4. Western Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

14.5. Western Europe Cancer Monoclonal Antibodies Market: Country Analysis

14.6. UK Cancer Monoclonal Antibodies Market

14.7. UK Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

14.8. UK Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

14.9. UK Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

14.10. Germany Cancer Monoclonal Antibodies Market

14.11. Germany Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

14.12. Germany Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

14.13. Germany Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

14.14. France Cancer Monoclonal Antibodies Market

14.15. France Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

14.16. France Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

14.17. France Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

15. Eastern Europe Cancer Monoclonal Antibodies Market

15.1. Eastern Europe Cancer Monoclonal Antibodies Market Overview

15.1.1. Region Information

15.1.2. Market Information

15.1.3. Background Information

15.1.4. Government Initiatives

15.1.5. Regulatory Bodies

15.1.6. Regulations

15.1.7. Major Associations

15.1.8. Taxes Levied

15.1.9. Corporate Tax Structure

15.1.10. Investments

15.1.11. Major Companies

15.2. Eastern Europe Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

15.3. Eastern Europe Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

15.4. Eastern Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

15.5. Eastern Europe Cancer Monoclonal Antibodies Market: Country Analysis

15.6. Russia Cancer Monoclonal Antibodies Market

15.7. Russia Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

15.8. Russia Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

15.9. Russia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

16. North America Cancer Monoclonal Antibodies Market

16.1. North America Cancer Monoclonal Antibodies Market Overview

16.1.1. Region Information

16.1.2. Market Information

16.1.3. Background Information

16.1.4. Government Initiatives

16.1.5. Regulations

16.1.6. Regulatory Bodies

16.1.7. Major Associations

16.1.8. Taxes And Duties

16.1.9. Corporate Tax Structure

16.1.10. Investments

16.1.11. Major Companies

16.2. North America Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

16.3. North America Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

16.4. North America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

16.5. North America Cancer Monoclonal Antibodies Market: Country Analysis

16.6. USA Cancer Monoclonal Antibodies Market

16.7. USA Cancer Monoclonal Antibodies Market Overview

16.7.1. Region Information

16.7.2. Market Information

16.7.3. Background Information

16.7.4. Government Initiatives

16.7.5. Regulatory Bodies

16.7.6. Regulations

16.7.7. Major Associations

16.7.8. Taxes Levied

16.7.9. Corporate Tax Structure

16.7.10. Investments

16.7.11. Major Companies

16.8. USA Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

16.9. USA Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

16.10. USA Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

17. South America Cancer Monoclonal Antibodies Market

17.1. South America Cancer Monoclonal Antibodies Market Overview

17.1.1. Region Information

17.1.2. Market Information

17.1.3. Background Information

17.1.4. Government Initiatives

17.1.5. Regulations

17.1.6. Regulatory Bodies

17.1.7. Major Associations

17.1.8. Taxes And Duties

17.1.9. Corporate Tax Structure

17.1.10. Investments

17.1.11. Major Companies

17.2. South America Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

17.3. South America Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

17.4. South America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

17.5. South America Cancer Monoclonal Antibodies Market: Country Analysis

17.6. Brazil Cancer Monoclonal Antibodies Market

17.7. Brazil Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

17.8. Brazil Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

17.9. Brazil Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

18. Middle East Cancer Monoclonal Antibodies Market

18.1. Middle East Cancer Monoclonal Antibodies Market Overview

18.1.1. Region Information

18.1.2. Market Information

18.1.3. Background Information

18.1.4. Government Initiatives

18.1.5. Regulations

18.1.6. Regulatory Bodies

18.1.7. Major Associations

18.1.8. Taxes Levied

18.1.9. Corporate Tax Structure

18.1.10. Investments

18.1.11. Major Companies

18.2. Middle East Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

18.3. Middle East Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

18.4. Middle East Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

19. Africa Cancer Monoclonal Antibodies Market

19.1. Africa Cancer Monoclonal Antibodies Market Overview

19.1.1. Region Information

19.1.2. Market Information

19.1.3. Background Information

19.1.4. Government Initiatives

19.1.5. Regulations

19.1.6. Regulatory Bodies

19.1.7. Major Associations

19.1.8. Taxes And Duties

19.1.9. Corporate Tax Structure

19.1.10. Investments

19.1.11. Major Companies

19.2. Africa Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

19.3. Africa Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

19.4. Africa Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

20. Global Cancer Monoclonal Antibodies Market Competitive Landscape

20.1. Company Profiles

20.2. F. Hoffmann-La Roche Ltd

20.2.1. Company Overview

20.2.2. Products And Services

20.2.3. Business Strategy

20.2.4. Financial Overview

20.3. Merck & Co., Inc.

20.3.1. Company Overview

20.3.2. Products And Services

20.3.3. Business Strategy

20.3.4. Financial Overview

20.4. Bristol Myers Squibb Company

20.4.1. Company Overview

20.4.2. Products And Services

20.4.3. Business Strategy

20.4.4. Financial Overview

20.5. Johnson & Johnson

20.5.1. Company Overview

20.5.2. Products And Services

20.5.3. Business Strategy

20.5.4. Financial Overview

20.6. Amgen Inc.

20.6.1. Company Overview

20.6.2. Products And Services

20.6.3. Business Strategy

20.6.4. Financial Overview

21. Key Mergers And Acquisitions In The Cancer Monoclonal Antibodies Market

21.1. Ecolab Inc. To Acquire Purolite

21.2. Exelixis Inc. Acquired Gamamabs Pharma SA’s AMHR2 Antibody Technology

21.3. Sanofi Acquired Kymab Group Ltd.

21.4. Boehringer Ingelheim Acquired Preclinical Antibody Pipeline From Northern Biologics Inc.

21.5. Servier Acquired Symphogen A/S

21.6. Gilead Sciences Acquired Forty Seven

21.7. True North Acquired Stake In Biocon Biologics

21.8. Catalent Inc. Acquired Bristol Myers Squibb’s Oral Dose Manufacturing Facility

21.9. Bristol Myers Acquired Celgene

22. Cancer Monoclonal Antibodies Market Opportunities And Strategies

22.1. Global Cancer Monoclonal Antibodies Market In 2025 – Countries Offering Most New Opportunities

22.2. Global Cancer Monoclonal Antibodies Market In 2025 – Segments Offering Most New Opportunities

22.3. Global Cancer Monoclonal Antibodies Market In 2025 – Growth Strategies

22.3.1. Market Trend Based Strategies

22.3.2. Competitor Strategies

23. Cancer Monoclonal Antibodies Market, Conclusions and Recommendations

23.1. Conclusions

23.2. Recommendations

23.2.1. Product

23.2.2. Place

23.2.3. Price

23.2.4. Promotion

23.2.5. People

24. Appendix

24.1. Market Data Sources

24.2. Research Methodology

24.3. Currencies

24.4. Research Inquiries

24.5. The Business Research Company

24.6. Copyright and Disclaimer

List Of Tables

Table 1: Global Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Table 2: Global Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 3: Global Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 4: Global Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 5: Global Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 6: Global Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 7: Global Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 8: Global Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 9: Global Cancer Monoclonal Antibodies Market, By Region, Historic and Forecast, 2015 – 2020, 2025F, 2030F, %

Table 10: Global Cancer Monoclonal Antibodies Market, By Region, Historic and Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 11: Global Cancer Monoclonal Antibodies Market, By Country, Historic and Forecast, 2015 – 2020, 2025F, 2030F, %

Table 12: Global Cancer Monoclonal Antibodies Market, By Country, Historic and Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 13: Asia Pacific GDP Per Capita, 2015-2020, $

Table 14: Asia Pacific, Population By Age Group, By Country, 2015-2023, Thousands

Table 15: Asia Pacific Cancer Prevalence, Estimated Average Expenditure, 2019, $

Table 16: Asia-Pacific Oncology Drugs Market, 2015-2025, $Billion

Table 17: Asia-Pacific Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Table 18: Asia-Pacific Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 19: Asia-Pacific Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 20: Asia-Pacific Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 21: China GDP Per Capita, 2015-2020, $

Table 22: China, Population By Age Group, 2015-2023, Thousands

Table 23: China Cancer Prevalence, Estimated Average Expenditure, 2019, $

Table 24: China Oncology Drugs Market, 2015-2025, $Billion

Table 25: China Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Table 26: China Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 27: China Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 28: China Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 29: India Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Table 30: India Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 31: India Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 32: India Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 33: Japan Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Table 34: Japan Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 35: Japan Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 36: Japan Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 37: Australia Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Table 38: Australia Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 39: Australia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 40: Australia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 41: Indonesia Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Table 42: Indonesia Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 43: Indonesia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 44: Indonesia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 45: South Korea Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Table 46: South Korea Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 47: South Korea Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 48: South Korea Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 49: Western Europe GDP Per Capita, 2015-2020, $

Table 50: Western Europe Population By Age Group, By Country, 2015-2023, Thousands

Table 51: Western Europe Estimated Average Expenditure, Cancer Prevalence, 2019

Table 52: Western Europe Oncology Drugs Market, 2015-2025, $Billion

Table 53: Western Europe Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Table 54: Western Europe Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 55: Western Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 56: Western Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 57: UK Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Table 58: UK Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 59: UK Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 60: UK Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 61: Germany Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Table 62: Germany Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 63: Germany Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 64: Germany Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 65: France Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Table 66: France Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 67: France Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 68: France Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 69: Eastern Europe GDP Per Capita, 2015-2020, $

Table 70: Eastern Europe Population By Age Group, By Country, 2015-2023, Thousands

Table 71: Eastern Europe Estimated Average Expenditure, Cancer Prevalence, 2019

Table 72: Eastern Europe Oncology Drugs Market, 2015-2025, $Billion

Table 73: Eastern Europe Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Table 74: Eastern Europe Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 75: Eastern Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 76: Eastern Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 77: Russia Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Table 78: Russia Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 79: Russia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 80: Russia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 81: North America GDP Per Capita, 2015-2020, $

Table 82: North America Population By Age Group, By Country, 2015-2023, Thousands

Table 83: North America Estimated Average Expenditure, Cancer Prevalence, 2019

Table 84: North America Oncology Drugs Market, 2015-2025, $Billion

Table 85: North America Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Table 86: North America Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 87: North America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 88: North America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 89: USA GDP Per Capita, 2015-2020, $

Table 90: USA Population By Age Group, 2015-2023, Thousands

Table 91: USA Estimated Average Expenditure, Cancer Prevalence, 2019

Table 92: North America Oncology Drugs Market, 2015-2025, $Billion

Table 93: USA Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Table 94: USA Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 95: USA Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 96: USA Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 97: South America GDP Per Capita, 2015-2020, $

Table 98: South America Population By Age Group, By Country, 2015-2023, Thousands

Table 99: South America Estimated Average Expenditure, Cancer Prevalence, 2019

Table 100: South America Oncology Drugs Market, 2015-2025, $Billion

Table 101: South America Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Table 102: South America Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 103: South America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 104: South America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 105: Brazil Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Table 106: Brazil Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 107: Brazil Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 108: Brazil Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 109: Middle East GDP Per Capita, 2015-2020, $

Table 110: Middle East Population By Age Group, By Country, 2015-2023, Thousands

Table 111: Middle East Oncology Drugs Market, 2015-2025, $Billion

Table 112: Middle East Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Table 113: Middle East Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 114: Middle East Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 115: Middle East Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 116: Africa GDP Per Capita, 2015-2020, $

Table 117: Africa Population By Age Group, By Country, 2015-2023, Thousands

Table 118: Africa Oncology Drugs Market, 2015-2025, $Billion

Table 119: Africa Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Table 120: Africa Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Table 121: Africa Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Table 122: Africa Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million

Table 123: Global Cancer Monoclonal Antibodies Market, Key Competitor Estimated Market Shares, 2020, Percentage (%)

Table 124: F. Hoffmann-La Roche Ltd – Financial Performance, 2016 – 2020, $ Billion

Table 125: Merck & Co., Inc. – Financial Performance, 2016 – 2020, $ Billion

Table 126: Bristol Myers Squibb Company – Financial Performance, 2016 – 2020, $ Billion

Table 127: Johnson & Johnson – Financial Performance, 2016 – 2020, $ Billion

Table 128: Amgen Inc. – Financial Overview, 2016 - 2020, $ Billion

Table 129: Global Cancer Monoclonal Antibodies Market Size Gain ($ Million), 2020 – 2025, By Country

Table 130: Global Cancer Monoclonal Antibodies Market Size Gain ($ Million), Segmentation By Monoclonal Antibody Therapies, 2020 – 2025

Table 131: Global Cancer Monoclonal Antibodies Market Size Gain ($ Million), Segmentation By Application, 2020 – 2025

Table 132: Global Cancer Monoclonal Antibodies Market Size Gain ($ Million), Segmentation By End User, 2020 – 2025

Table 133: Cancer Monoclonal Antibodies - Market Data Sources

List Of Figures

Figure 1: Global Cancer Monoclonal Antibodies Market Segmentation By Monoclonal Antibody Therapies

Figure 2: Global Cancer Monoclonal Antibodies Market Segmentation By Application

Figure 3: Global Cancer Monoclonal Antibodies Market Segmentation By End User

Figure 4: Global Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Figure 5: Global Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Figure 6: Global Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Figure 7: Global Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Figure 8: Global Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Figure 9: Global Cancer Monoclonal Antibodies Market, By Region, Historic and Forecast, 2015 – 2020, 2025F, 2030F, %

Figure 10: Global Cancer Monoclonal Antibodies Market, By Country, Historic and Forecast, 2015 – 2020, 2025F, 2030F, %

Figure 11: Asia-Pacific Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Figure 12: Asia-Pacific Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Figure 13: Asia-Pacific Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Figure 14: China Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Figure 15: China Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Figure 16: China Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Figure 17: India Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Figure 18: India Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Figure 19: India Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Figure 20: Japan Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Figure 21: Japan Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Figure 22: Japan Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Figure 23: Australia Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Figure 24: Australia Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Figure 25: Australia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Figure 26: Indonesia Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Figure 27: Indonesia Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Figure 28: Indonesia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Figure 29: South Korea Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Figure 30: South Korea Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Figure 31: South Korea Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Figure 32: Western Europe Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Figure 33: Western Europe Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Figure 34: Western Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Figure 35: UK Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Figure 36: UK Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Figure 37: UK Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Figure 38: Germany Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Figure 39: Germany Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Figure 40: Germany Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Figure 41: France Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Figure 42: France Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Figure 43: France Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Figure 44: Eastern Europe Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Figure 45: Eastern Europe Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Figure 46: Eastern Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Figure 47: Russia Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Figure 48: Russia Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Figure 49: Russia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Figure 50: North America Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Figure 51: North America Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Figure 52: North America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Figure 53: USA Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Figure 54: USA Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Figure 55: USA Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Figure 56: South America Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Figure 57: South America Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Figure 58: South America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Figure 59: Brazil Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Figure 60: Brazil Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Figure 61: Brazil Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Figure 62: Middle East Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Figure 63: Middle East Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Figure 64: Middle East Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Figure 65: Africa Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million

Figure 66: Africa Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million

Figure 67: Africa Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %

Figure 68: Global Cancer Monoclonal Antibodies Market, Key Competitor Estimated Market Shares, 2020, Percentage (%)

Figure 69: F. Hoffmann-La Roche Ltd – Financial Performance, 2016 – 2020, $ Billion

Figure 70: Merck & Co., Inc. – Financial Performance, 2016 – 2020, $ Billion

Figure 71: Bristol Myers Squibb Company – Financial Performance, 2016 – 2020, $ Billion

Figure 72: Johnson & Johnson – Financial Performance, 2016 – 2020, $ Billion

Figure 73: Amgen Inc. – Financial Overview, 2016 – 2020, $ Billion

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the hiv drugs market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the rituximab biosimilars market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the microbiome market research report 2022 with industry size, share, segments and market growth

CAR-T Therapy Market 2021 - By Target Antigen (CD19, CD22, BCMA), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma), And By Region, Opportunities And Strategies – Global Forecast To 2030

View Report

Central Nervous System Drugs Market 2021 - By Type (Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other CNS Drugs), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Intravenous, Intranasal/ Inhalation), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Over-The-Counter Drugs, Prescription-Based Drugs), And By Region, Opportunities And Strategies – Global Forecast To 2030

View Report

HIV Drugs Global Market Report 2024 – By Type (Nucleoside Reverse Transcriptase Inhibitors (NRT’s), Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT’s), Protease Inhibitors, Integrase strand transfer inhibitors (INSTIs), Other Types), By Administration (Oral, Parenteral), By Application (Hospital Pharmacies, Retail Pharmacies, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Antidepressants Global Market Report 2024 – By Product (Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-norepinephrine Reuptake Inhibitor (SNRI), Tricyclic Antidepressant (TCA), Monoamine Oxidase Inhibitor (MAOI)), By Drug Class (Monoamine Oxidase Inhibitors, Serotonin Antagonist And Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Tricyclic Antidepressants), By Depressive Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Bi-Specific MAbS Global Market Report 2024 – By Type (Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab), By Product Type (In Vivo, In Vitro), By Indication (Cancer, Hemophilia A, Ophthalmic), By End Use (Hospitals, Research Institutes, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Vitamin and Minerals Global Market Report 2024 – By Type (Multivitamin, Single Vitamin, Multi Mineral, Single Mineral), By Application (Energy And Weight Management, General Health, Bone And Joint Health, Gastrointestinal Health, Immunity, Cardiac Health, Diabetes, Anti-Cancer, Other Applications), By Distribution Channel (Pharmacies And Drug Stores, Supermarkets And Hypermarkets, Online Channels), By End-User (Adults, Geriatric, Pregnant Women, Children, Infants) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Oligonucleotide Therapy Global Market Report 2024 – By Type (Antisense Oligonucleotide, Aptamer, Other Types), By Application (Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Other End-User), By End User (Hospitals, Research Institutes) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Cell Therapy Global Market Report 2024 – By Technique (Stem Cell Therapy, Cell Vaccine, Adoptive Cell Transfer (ACT), Fibroblast Cell Therapy, Chondrocyte Cell Therapy), By Therapy Type (Allogeneic Therapies, Autologous Therapies), By Application (Oncology, Cardiovascular Disease (CVD), Orthopedic, Wound Healing, Other Applications) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Cancer Monoclonal Antibodies Global Market Opportunities And Strategies To 2030: COVID 19 Growth And Change

Cancer Monoclonal Antibodies Global Market Opportunities And Strategies To 2030: COVID 19 Growth And Change

Cancer Monoclonal Antibodies Market Definition

Cancer Monoclonal Antibodies Market Size

Cancer Monoclonal Antibodies Market Drivers

Cancer Monoclonal Antibodies Market Restraints

Cancer Monoclonal Antibodies Market Trends

Opportunities And Recommendations In The Cancer Monoclonal Antibodies Market

Cancer Monoclonal Antibodies Market Segmentation

Cancer Monoclonal Antibodies Market Competitive Landscape

Major Competitors are:

Other Competitors Include:

Table Of Contents

List Of Tables

List Of Figures

Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company

Global Gene Therapy Market 2022 – Market Opportunities And Strategies

Global Protein Purification And Isolation Market 2022 – Market Opportunities And Strategies

What Is The Pharmaceutical Processing Seals Market Overview In 2022?

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the hiv drugs market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the rituximab biosimilars market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the microbiome market research report 2022 with industry size, share, segments and market growth

CAR-T Therapy Market 2021 - By Target Antigen (CD19, CD22, BCMA), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma), And By Region, Opportunities And Strategies – Global Forecast To 2030

Frequently Asked Questions